1. Introduction {#sec1-ijms-21-00475}
===============

Allergic contact dermatitis (ACD) is an inflammatory skin reaction to subthreshold exposures to low-molecular-weight compounds called haptens \[[@B1-ijms-21-00475]\]. Skin manifestations such as pruritic skin lesions at sites of allergen exposure often manifest chronically, and therefore they represent a rising global burden on the healthcare system \[[@B2-ijms-21-00475],[@B3-ijms-21-00475]\].

A well-established experimental murine model of ACD is 2,4-dinitro-1-fluorobenzene (DNFB)-induced cutaneous contact hypersensitivity (CHS). The inflammatory response in CHS develops in two distinct phases \[[@B4-ijms-21-00475],[@B5-ijms-21-00475]\]. In the sensitization phase, activation of epidermal Langerhans cells and dermal dendritic cells (DCs) is promoted by haptenized proteins \[[@B4-ijms-21-00475]\]. Maturation-induced migration of antigen-presenting cells into the regional lymph nodes for initiation of hapten-specific T cell responses along chemokine gradients involves sequential upregulation of chemokine receptors \[[@B6-ijms-21-00475]\]. On the other hand, recent findings have suggested that DCs may also be required for the maintenance of immune tolerance in CHS \[[@B7-ijms-21-00475]\]. In the elicitation response, re-challenge with DNFB provokes a regulated skin immune response associated with effector T cell recruitment, which peaks 24 h post challenge \[[@B8-ijms-21-00475]\].

The endocannabinoid system includes the cannabinoid receptors, their endogenous ligands (endocannabinoids), and cannabinoid synthesizing and metabolizing enzymes \[[@B9-ijms-21-00475]\]. Cannabinoid receptor 1 (CB1), to which the psychotropic effects of 9-tetrahydrocannabinol (9-THC) have been attributed, is expressed mainly in the central nervous system \[[@B10-ijms-21-00475],[@B11-ijms-21-00475],[@B12-ijms-21-00475],[@B13-ijms-21-00475],[@B14-ijms-21-00475]\]. In contrast, cannabinoid receptor 2 (CB2) is expressed primarily by immune cells and has been found to play a key immunomodulatory role in various physiological and pathophysiological conditions \[[@B10-ijms-21-00475],[@B11-ijms-21-00475],[@B12-ijms-21-00475],[@B15-ijms-21-00475],[@B16-ijms-21-00475],[@B17-ijms-21-00475],[@B18-ijms-21-00475],[@B19-ijms-21-00475]\]. Interestingly, CB1 and CB2 are expressed in keratinocytes \[[@B20-ijms-21-00475],[@B21-ijms-21-00475]\] and are involved in their proliferation and differentiation \[[@B22-ijms-21-00475]\]. Moreover, we and others have demonstrated that CB1 and CB2 and their endogenous ligands are involved in skin allergies. Genetic deletion of both CB1 and CB2 enhances contact allergic inflammation, with non-redundant roles for each cannabinoid receptor in the allergic response to DNFB \[[@B21-ijms-21-00475]\]. On the other hand, CB2-specific antagonists/inverse agonists have been reported to alleviate chronic inflammation in mice, suggesting that there may be complex CB2-dependent regulation of inflammatory skin immune responses \[[@B23-ijms-21-00475],[@B24-ijms-21-00475]\].

CB2 signaling can further affect the basic functions of DCs, which represent key cellular players in allergic skin responses. A prior study demonstrated that treatment with a CB2 agonist inhibited DC migration towards CCL19 and the expression of matrix metalloproteinase 9 \[[@B25-ijms-21-00475]\]. We showed previously that lipopolysaccharide (LPS)-stimulated bone marrow (BM) derived-dendritic cells from *Cnr2^−/−^* mice secrete higher levels of several cytokines, including tumor necrosis factor (TNF), interleukin (IL)-6 and IL-12, as well as transforming growth factor-β (TGF-β) \[[@B26-ijms-21-00475]\]. However, the specific role of CB2 in modulating DC-dependent sensitization for CHS has not yet been studied. Additionally, while the protective effects of CB1 in CHS have been attributed to its presence on keratinocytes \[[@B27-ijms-21-00475],[@B28-ijms-21-00475]\], a potential role of CB1 in DCs has not been assessed up to now.

In this study, we examined the specific influence of CB1 and CB2 on the capacity of DCs to induce CHS and the specific role of CB2 in DC maturation and migration.

2. Results {#sec2-ijms-21-00475}
==========

2.1. Reduced Contact Hypersensitivity upon Adoptive Transfer of Haptenized Cnr2^−/−^ Dendritic Cells {#sec2dot1-ijms-21-00475}
----------------------------------------------------------------------------------------------------

We utilized an in vivo adoptive transfer model to study the effect of CB1 and/or CB2 deficiency on the capacity of haptenized DCs to sensitize naïve mice for contact hypersensitivity (CHS). For this, we injected DNFB-haptenized DCs generated from the bone marrow (BM) of *Cnr1^−/−^/Cnr2^−/−^*, *Cnr1^−/−^*, *Cnr2^−/−^* or wild type (WT) mice into naïve WT recipients. Animals were subsequently challenged twice with DNFB and ear swelling was measured after 48 h ([Figure 1](#ijms-21-00475-f001){ref-type="fig"}a). DNFB-challenged WT mice showed allergic ear swelling after sensitization with haptenized WT DCs ([Figure 1](#ijms-21-00475-f001){ref-type="fig"}b). However, the CHS response was significantly reduced in mice sensitized with haptenized *Cnr1^−/−^/Cnr2^−/−^* DCs as compared to recipients injected with WT DCs. A reduced ear swelling reaction to DNFB was also observed in WT animals after adoptive transfer of *Cnr2^−/−^* DCs, whereas induction of CHS was not affected in *Cnr1^−/−^* DC-treated WT recipients.

To investigate whether CB1 and CB2 also modulated the response of the host, haptenized DCs were injected into *Cnr1^−/−^/Cnr2^−/−^*, *Cnr1^−/−^*, and *Cnr2^−/−^* recipient mice as well as into WT controls. Again, recipient mice were subsequently challenged twice with DNFB ([Figure 1](#ijms-21-00475-f001){ref-type="fig"}a). Adoptive transfer of WT cells into *Cnr1^−/−^/Cnr2^−/−^* or *Cnr1^−/−^* mice, but not *Cnr2^−/−^* mice, induced exacerbated allergic responses when compared to WT recipients ([Figure 1](#ijms-21-00475-f001){ref-type="fig"}b). These findings indicate that CB1 affects the host immune response during CHS, while CB2 expression on DCs in the sensitization phase alters their ability to initiate CHS responses.

Thus, CB1 signaling in DCs is dispensable during naive T cell priming but is critical in host cells. We therefore focused our subsequent analyses on the specific role of CB2 in DC maturation and migration.

2.2. Reduced Expression of Chemokine Receptors on Cnr2^−/−^ and WT BM-DCs {#sec2dot2-ijms-21-00475}
-------------------------------------------------------------------------

It is well established that the chemokine receptors CCR7 and CXCR4 and their cognate ligands CCL19/CCL21 and CXCL12, respectively, are regulators of skin DC migration under inflammatory conditions \[[@B29-ijms-21-00475],[@B30-ijms-21-00475]\]. We therefore assessed expression of CCR7 and CXCR4 on BM-DCs of both genotypes by flow cytometry. Levels of both chemokine receptors did not differ between WT and *Cnr2^−/−^* DCs ([Figure 2](#ijms-21-00475-f002){ref-type="fig"}). However, upon Toll-like receptor 4 (TLR4) stimulation with LPS, upregulation of CCR7 expression was significantly lower on *Cnr2^−/−^* DCs when compared to WT cells. Furthermore, *Cnr2^−/−^* DCs exhibited lower CXCR4 expression levels as compared to WT cells after TLR4 or TLR9 ligation with LPS or CpG oligonucleotide 1668 (CpG), respectively ([Figure 2](#ijms-21-00475-f002){ref-type="fig"}).

To determine whether CB2 affects migration of DCs, we next examined the chemotactic capacity of WT and *Cnr2*^−/−^ DCs using in vitro transwell assays. For this, LPS or CpG stimulated BM-DCs were loaded into the upper well with or without addition of CCL19 in the bottom well. While migration of DCs was greatly increased in the presence of CCL19, WT and *Cnr2*^−/−^ BM-DCs migrated toward CCL19 in equivalent numbers ([Figure 3](#ijms-21-00475-f003){ref-type="fig"}). These data demonstrate that CB2 deficiency does not alter the chemotactic behavior of DCs in response to CCL19.

2.3. Reduced Expression of MHC Class II (MHC II) and Co-Stimulatory Molecules by Cnr2^−/−^ BM-DCs upon TLR Stimulation {#sec2dot3-ijms-21-00475}
----------------------------------------------------------------------------------------------------------------------

A prerequisite for CHS is the maturation of DCs during their migration to the draining LNs following exposure to antigen. We therefore examined the influence of CB2 on the maturation of BM-DCs from *Cnr2^−/−^* and WT mice by analyzing surface expression of MHC II and the co-stimulatory molecules CD40 and CD86 upon stimulation with LPS or CpG. We found reduced expression of MHC II on BM-DCs isolated from *Cnr2^−/−^* mice in comparison to WT BM-DCs in the naïve state and upon stimulation. Notably, higher expression levels of CD40 were observed in naïve *Cnr2^−/−^* BM-DCs when compared to WT BM-DCs. However, stimulation with LPS induced lower upregulation of CD40 on *Cnr2^−/−^* BM-DCs when compared to WT cells ([Figure 4](#ijms-21-00475-f004){ref-type="fig"}). In addition, CD86 expression was markedly enhanced in WT BM-DCs upon stimulation with CpG, while it was not affected in *Cnr2^−/−^* BM-DCs. Thus, CB2 affects upregulation of MHC II and co-stimulatory molecules upon maturation of DCs, a process required for naïve T cell stimulation.

Finally, we investigated possible CB2-mediated effects on immunoregulatory mechanisms in DCs. For this purpose, we analyzed expression of programmed death-ligand 1 (PD-L1) and PD-L2 on BM-DCs since both PD-1 ligands play a regulatory role in immune responses to contact allergens. Blocking PD-L1/PD-1 with monoclonal antibodies has been shown to enhance CHS reactions \[[@B25-ijms-21-00475],[@B31-ijms-21-00475]\], while interfering RNA-mediated silencing of PD-L2 on DCs inhibited the elicitation of CHS \[[@B32-ijms-21-00475]\]. Here, we found comparable expression of PD-L1 and PD-L2 on unstimulated and LPS-stimulated *Cnr2^−/−^* and WT BM-DCs ([Figure 5](#ijms-21-00475-f005){ref-type="fig"}a).

Finally, we studied the production of IL-10 by activated *Cnr2^−/−^* and WT BM-DCs. This anti-inflammatory cytokine has previously been shown to efficiently inhibit ear swelling responses in hapten-induced CHS when overexpressed in virally transduced DCs upon in vivo transfer \[[@B33-ijms-21-00475]\]. In our study, we found equivalent levels of IL-10 in the supernatants of stimulated *Cnr2^−/−^* and WT BM-DCs ([Figure 5](#ijms-21-00475-f005){ref-type="fig"}b), underscoring that neither expression of PD-1 ligands nor IL-10 production in BM-DCs in vitro is affected by CB2.

3. Discussion {#sec3-ijms-21-00475}
=============

In this study, we investigated the role of CB1 and CB2 in CHS induction by DNFB-haptenized DCs in vivo and the specific influence of CB2 in maturation and migration of DCs in vitro. Our data demonstrate that the absence of CB2 reduced the potential of haptenized DCs to induce CHS responses in mice. Adoptive transfers of DNFB-haptenized *Cnr2*^−/−^ or *Cnr1*^−/−^/*Cnr2*^−/−^ deficient DCs resulted in attenuated ear swelling while transfer of haptenized *Cnr1*^−/−^ DCs did not affect CHS in WT animals. These findings suggest that specifically CB2 affects DCs in a cell-intrinsic manner. Notably, host *Cnr2* deficiency did not alter ear swelling responses, whereas *Cnr1*-deficient recipients showed enhanced allergic responses upon transfer of WT DCs. Thus, CB1 expression by host cells, but not adoptively transferred donor cells, mediates protective effects. These results are in line with our previous findings showing that lack of CB1 expression in host keratinocytes leads to exacerbated CHS responses associated with increased expression of chemokines including CCL8 and the alarmin thymic stromal lymphopoietin TSLP \[[@B21-ijms-21-00475],[@B27-ijms-21-00475],[@B28-ijms-21-00475]\]. With these opposing roles of CB1 (host protection) and CB2 (maturation signal for haptenized DCs) in mind, we investigated changes in key functions of DCs that may be operative in CHS induction by haptenized DCs.

Various chemokines and their receptors have been functionally implicated in migration of DCs into the lymph node during CHS \[[@B34-ijms-21-00475],[@B35-ijms-21-00475],[@B36-ijms-21-00475]\]. Accordingly, it has been demonstrated that CCR7 mediates entry of both dermal and epidermal DCs into the lymphatic vessels and thus acts as a master regulator of DC migration under steady-state and inflammatory conditions \[[@B29-ijms-21-00475],[@B37-ijms-21-00475]\]. Additional studies have highlighted the functional involvement of the CXCL12-CXCR4 axis in CHS \[[@B30-ijms-21-00475],[@B38-ijms-21-00475],[@B39-ijms-21-00475]\]. CHS responses were impaired by CXCR4 antagonist administration during the sensitization phase in mice indicating that CXCL12-CXCR4 engagement was required for migration of cutaneous DCs \[[@B30-ijms-21-00475]\]. Here, we demonstrate that CB2 deficiency did not alter CCR7 and CXCR4 expression levels on unstimulated BM-DCs, but reduced TLR-mediated upregulation of both receptors on activated BM-DCs. This is surprising in the context of an earlier study demonstrating that activation of BM-DCs with a cocktail of TNF, IL-1β, IL-6, PGE2, and the CB2 agonist GP1a did not affect CCR7 upregulation. Here, Adhikary and coauthors harvested BM-DCs on day 7 of culture and further matured them for up to 2 days in the presence of the cytokine cocktail and PGE2 and the CB2 agonist \[[@B25-ijms-21-00475]\]. In our study, however, BM-DCs were utilized at day 6 and stimulated with the TLR agonist LPS according to established maturation protocols. Both maturation protocols induce distinct gene expression profiles and immune related functions in BM-DCs \[[@B40-ijms-21-00475]\]. Thus, the diverse findings from both studies can be explained by differences in the maturation states of BM-DCs.

Furthermore, Adhikary et al. showed that CB2 deficient BM-DCs matured with various cytokines migrated equally well towards CCL19 as WT BM-DCs \[[@B25-ijms-21-00475]\]. In our transwell migration assays, both, unstimulated as well as LPS or CpG-stimulated *Cnr2^−/−^* DCs, showed an equivalent migratory behavior towards CCL19 when compared to WT DCs. However, it is yet unresolved whether CCR7 expression levels potentially altered under in vivo conditions in activated *Cnr2^−/−^* DCs may affect their migratory behavior in CHS.

Additionally, we found that *Cnr2^−/−^* BM-DCs were impaired in TLR ligand-induced upregulation of MHC class II and the co-stimulatory molecules CD40 and CD86. It is possible that these phenotypic changes in *Cnr2^−/−^* DCs affect their capacity to activate T cells in CHS. In this context, blockade of the CD40-CD40L pathway during sensitization has been shown to inhibit T cell mediated responses and thus induce tolerance in murine CHS \[[@B41-ijms-21-00475]\]. CD40-CD40 ligand interactions have further been demonstrated to regulate migration of antigen-bearing DCs from skin to draining lymph nodes in vivo, ameliorating CHS responses in CD40L knockout mice after hapten sensitization \[[@B42-ijms-21-00475]\]. Furthermore, CD86 expression on DCs has been reported to be required for induction of CHS. Accordingly, injection of anti-CD86 antibodies before DNFB sensitization inhibited CHS development associated with reduced upregulation of CD80 and CD86 on DCs in the lymph nodes \[[@B43-ijms-21-00475],[@B44-ijms-21-00475]\]. This involvement of CD86 in CHS was further highlighted by a prior study demonstrating that topical application of cream-emulsified CD86 siRNA in mice after sensitization reduced CD86 expression of DCs in skin-draining lymph nodes and ameliorated the clinical manifestations of CHS \[[@B45-ijms-21-00475]\]. Hence, it is possible that *Cnr2* deficiency in haptenized DCs dampens induction of CHS responses due to reduced upregulation of co-stimulatory molecules, resulting ultimately in impaired induction of effector T cell responses \[[@B46-ijms-21-00475]\].

In conclusion, our findings confirm the importance of CB1 on host cells for protection from CHS and identified CB2 expression on DCs as a factor contributing to the development of the disease. CB2 plays a DC-intrinsic role that affects CHS induction in vivo. Loss of CB2 signaling resulted in reduced upregulation of CCR7 and CXCR4 on activated BM-DCs but did not affect in vitro migration behavior of unstimulated BM-DCs in response to a CCR7 ligand. CB2 deficiency further impaired upregulation of MHC class II and co-stimulatory molecules in DCs under inflammatory conditions in vitro and may thus be operative in DC-dependent mechanisms involved in T cell activation in CHS. Thus, targeting CB2 signaling specifically in DCs has therapeutic potential for the treatment of atopic dermatitis, which represents a considerable burden on patients and healthcare systems.

4. Materials and Methods {#sec4-ijms-21-00475}
========================

4.1. Animals {#sec4dot1-ijms-21-00475}
------------

Mice with a genetic deletion of the *Cnr1/2* (*Cnr1/2^−/−^*), *Cnr1* (*Cnr1^−/−^*), and *Cnr2* (*Cnr2^−/−^*) gene on the C57BL/6J background \[[@B46-ijms-21-00475]\] and their littermate controls were bred and housed in the Specific Pathogen Free (SPF) animal facility of the House for Experimental Therapy (University of Bonn, Germany) and ZTE Münster. All experiments were conducted according to the institutional and national guidelines for the care and use of laboratory animals and were approved by the local government authorities (Landesamt für Natur, Umwelt und Verbraucherschutz NRW, Germany, date of document: 17/04/2008).

4.2. Contact Hypersensitivity {#sec4dot2-ijms-21-00475}
-----------------------------

Mature DCs were haptenized with 2,5 mM dinitrobenzene sulfonic acid (DNBS, MP Biomedicals, Solon, OH, USA), the water-soluble analogue of the obligate contact sensitizer 1-fluoro-2,4-dinitrobenzene (DNFB). For sensitization, naïve mice received two inguinal s.c. injections of 5 × 10^5^ haptenized DCs. For elicitation of CHS, ears of mice were painted with 10 µL of 0.3% DNFB on day 5, a second challenge was performed on day 12. Ear thickness was measured 48 h hours after the second challenge using a spring-loaded caliper (Kroeplin, Schlüchtern, Germany). Ear swelling was calculated in each mouse as the difference in ear thickness between the unchallenged and challenged ear.

4.3. Generation of BM-DCs {#sec4dot3-ijms-21-00475}
-------------------------

Bone marrow cells were cultured as described previously \[[@B47-ijms-21-00475],[@B48-ijms-21-00475]\]. In brief, bone marrow cells from *Cnr1^−/−^*, *Cnr2*^−/−^ and *Cnr1*^−/−^/*Cnr2*^−/−^ mice were seeded at 5 × 10^5^ cells/mL in DMEM supplemented with 10% FCS, 1% MEM/NEAA, 1% Penicillin/Streptavidin 0.1% β-Mercaptoethanol (all from Thermo Fisher Scientific, Inchinnan, UK) and 10% conditioned medium of B16 cells. Medium was exchanged on day 3 and cells stimulated on day 5 with either 100 ng/mL *Escherichia coli* Lipopolysaccharide (LPS) Serotype 0127:B8 (Sigma-Aldrich, Saint Louis, MO, USA) or 1 nmol/mL CpG1668 (TIB MOLBIOL, Berlin, Germany). After 16 h of stimulation, cells were harvested and analyzed by FACS or transferred in the migration assay.

4.4. Transwell Migration Assays {#sec4dot4-ijms-21-00475}
-------------------------------

GM-CSF generated BM-DCs were stimulated at day 5 of culturing with LPS (Sigma-Aldrich, Saint Louis, MO, USA) or CpG1668 (TIB MOLBIOL, Berlin, Germany) and 4 × 10^5^ cells transferred at day 6 to the upper chamber compartment of a 5 µm pore size transwell plate (Corning, Kennebunk, ME, USA). The lower well compartments were filled either with media only or 200 ng/mL CCL19 (R&D Systems, Minneapolis, MN, USA). The concentration of 200 ng/mL recombinant CCL19 was selected in accordance with earlier studies demonstrating optimal chemotactic responses at these concentrations \[[@B41-ijms-21-00475],[@B48-ijms-21-00475]\]. Cells were allowed to migrate for 4 h at 37 °C in 5% CO~2~. Cell counts of the migrated DCs harvested from the lower chambers were determined by FACS.

4.5. FACS Analysis {#sec4dot5-ijms-21-00475}
------------------

Fluorescence staining was performed using the following antibodies: anti-CD11c (AF448 labeled), anti-CD11b (BV510 labeled) anti--I-Ab (BV421 labeled), anti-CCR7 (BV421 labeled), anti-CXCR4 (APC labeled), anti-PD-L1 (APC labeled), anti-PD-L2 (PE labeled) all from Biolegend (San Diego, CA, USA) and anti-CD40 (APC labeled) and anti-CD86 (PE labeled) from eBioscience (San Diego, CA, USA). Fluorescence was analyzed using a FACS Canto™ II (Becton Dickinson, Heidelberg, Germany) flow cytometer and Flowjo™ software (version 10.0.8, FlowJoLLC, Ashland, OR, USA).

4.6. Elisa {#sec4dot6-ijms-21-00475}
----------

IL-10 in cell culture supernatants was measured using ELISAs according to the manufacturer's instructions (Biolegend, San Diego, CA, USA). Detection limits for IL-10 were 2000 pg/mL.

4.7. Statistical Analysis {#sec4dot7-ijms-21-00475}
-------------------------

Statistically significant differences were calculated with the non-parametric Mann-Whitney U-test using SPSS software (version 25, IBM Corp., Armonk, NY, USA) and GraphPad Prism (version 8.00 for Mac OS X, La Jolla, CA, USA). \* *p* \< 0.05; \*\* *p* \< 0.01.

We thank K. Poppensieker for excellent technical assistance.

Conceptualization, E.G., A.M.K., S.S., J.A.; methodology, E.G., A.M.K., S.S., J.V., J.A.; formal analysis, E.G., A.M.K., S.S., J.V., J.A.; investigation, E.G., A.M.K., S.S., J.V., J.A.; writing---original draft preparation, E.G., A.M.K., S.S., R.L.D., J.V., J.A.; writing---review and editing, E.G., A.M.K., S.S., R.L.D.; J.V., B.B., T.T., A.Z., J.A.; visualization, E.G., A.M.K., S.S., J.V., J.A.; supervision, E.G., S.S., T.T., J.A.; funding acquisition, E.G., S.S., A.Z., J.A. All authors have read and agreed to the published version of the manuscript.

This study was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft) DFG-FOR926 to Judith Alferink, Evelyn Gaffal and Andreas Zimmer; DFG EXC 1003; Grant FF-2014-01 Cells in Motion--Cluster of Excellence, Münster, Germany to Judith Alferink; IZKF (University of Münster) Alf3/018/16 to Judith Alferink; IMF (University Münster) (grant I-ST111423 and grant I-DL121204) to Judith Alferink; DFG SCHE692/3-1, SCHE692/4-1 to Stefanie Scheu; Strategic Research Fund of the Heinrich Heine University Düsseldorf to Stefanie Scheu; Andreas Zimmer is a member of the DFG EXC 1023 Cluster of Excellence ImmunoSensation (EXC 1023); support by the Open Access Publication Fund of the Otto von Guericke University, Magdeburg.

The authors declare no conflict of interest.

9-THC

9-tetrahydrocannabinol

ACD

Allergic contact dermatitis

AF

Alexa Fluor

APC

allophycocyanin

BM-DCs

Bone marrow derived dendritic cells

BV

Brilliant Violet

CB/Cnr

Cannabinoid receptor

CCL/CXCL

Chemokine ligands of the CC and CXC classes

CCR/CXCR

Chemokine receptors of the CC and CXC classes

CHS

contact hypersensitivity

CpG

CpG Oligonucleotide 1668

DCs

dendritic cells

DMEM

Dulbecco modified Eagle medium

DNFB

2,4-dinitro-1-fluorobenzene

eCBS

Endocannabinoid system

FCS

Fetal calf serum

GM-CSF

granulocyte-macrophage colony-stimulating factor

Ig

Immunoglobulin

IL

interleukin

KO

knock out

LPS

lipopolysaccharide

mAb

monoclonal antibody

2-ME

2-mercaptoethanol

MEM/NEAA

Minimum essential medium/Non-essential amino acids

MHC

Major histocompatibility complex

PE

phycoerythrin

s.c.

subcutaneously

SEM

standard error of the mean

TH

T helper

9-THC

9-tetrahydrocannabinol

TLR

Toll-like receptor

TSLP

thymic stromal lymphopoietin

WT

wild type

![Reduced hapten-induced contact hypersensitivity upon transfer of cannabinoid receptor 2 (CB2)-deficient dendritic cells (DCs) into recipient mice. (**a**) Mice were sensitized (S) by subcutaneous (s.c.) injection of haptenized DCs and challenged (C) with 2,4-dinitro-1-fluorobenzene (DNFB). Ear swelling (M) was measured 48 h after the second challenge. (**b**) Mean ear swelling 48 h after the second challenge with DNFB (± SEM, *n* = 5 mice/group) in wild type (WT), *Cnr1/2*^−/−^, *Cnr1*^−/−^ and *Cnr2*^−/−^ mice sensitized with WT DCs, *Cnr1*^−/−^*/Cnr2*^−/−^ DCs (top), *Cnr1*^−/−^ DCs (middle) and *Cnr2*^−/−^ DCs (bottom). Experiments were repeated two times with similar results. \* *p* \< 0.05, \*\* *p* \< 0.01.](ijms-21-00475-g001){#ijms-21-00475-f001}

![Reduced expression of the chemokine receptors CCR7 and CXCR4 on activated CB2-deficient BM-DCs. BM-DCs from WT (white bars) or *Cnr2*^−/−^ (black bars) mice were cultured for 16 h in the absence (unstim) or presence of 1 nmol/mL CpG or 100 ng/mL lipopolysaccharide (LPS). Surface expression of CCR7 and CXCR4 was analyzed by flow cytometry. Data show median fluorescence intensity (MFI) ± SEM (*n* = 4--5 animals/group). \* *p* \< 0.05.](ijms-21-00475-g002){#ijms-21-00475-f002}

![In vitro migration of activated BM-DCs towards CCL19 is not affected by CB2 deficiency. Migratory behavior of BM-DCs from WT (*n* = 5) and *Cnr2*^−/−^ (*n* = 5) mice in transwell migration assays in response to 200 ng/mL CCL19 or medium only. CpG or LPS activated WT or *Cnr2*^−/−^ BM-DCs were seeded in the upper transwell chambers. After 4 h cells were collected in the bottom well and cell counts determined. Data show mean values ± SD (*n* = 4--5 animals/group). \*\* *p* \< 0.01.](ijms-21-00475-g003){#ijms-21-00475-f003}

![Reduced surface expression of MHC II and co-stimulatory molecules by *Cnr2*^−/−^ BM-DCs after Toll-like receptor (TLR) stimulation. Surface expression of MHC II, CD40, and CD86 by WT (white bars) or *Cnr2*^−/−^ (black bars) BM-DCs cultured for 16 h in the absence (unstim) or presence of 1 nmol/mL CpG or 100 ng/mL LPS. Data show median fluorescence intensity (MFI) ± SEM (*n* = 4--5 animals/group). \* *p* \< 0.05.](ijms-21-00475-g004){#ijms-21-00475-f004}

![Equivalent surface expression of programmed death-ligand 1 (PD-L1), PD-L2 and IL-10 production by *Cnr2*^−/−^ and WT BM-DCs after TLR4 stimulation. (**a**) Surface expression of PD-L1 and PD-L2 by WT (white bars) or *Cnr2*^−/−^ (black bars) BM-DCs cultured for 16 h in the absence (unstim) or presence of 100 ng/mL LPS. (**b**) Production of IL-10 by WT (white bars) or *Cnr2*^−/−^ (black bars) BM-DCs cultured for 16 h in the absence (unstim) or presence of 100 ng/mL LPS. Data show median fluorescence intensity (MFI) ± SEM (*n* = 3-4 animals/group).](ijms-21-00475-g005){#ijms-21-00475-f005}
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